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Fecal transplantation: passing Fashion or here to 
stay?
Tyrone Pitt
ABSTRACT
Several trillions of bacteria, distributed among more than 1,000 species, are natural 
inhabitants of the human intestinal tract and constitute what is now known as the 
gut microbiota. Although its composition varies within and between individuals with 
age, diet, and health status, it is becoming increasingly recognized that imbalances 
in the bacterial microbiota (dysbiosis) are linked to a number of conditions such 
as antibiotic-associated diarrhea, inflammatory bowel disease, and obesity, among 
others. Fecal transplantation where a preparation of stool from a microbiologically 
screened donor is administered into the colon of an affected recipient has been 
shown to be highly effective for the treatment of recurrent Clostridium difficile 
infection. Several trials of this therapy are now underway for gut dysbiosis in a 
number of patient disease groups raising concerns on the risk of transmission of 
infectious agents from donor to recipient, possible long-term adverse consequences 
of treatment, and effective regulation of the stool material used for the procedure. 
A worrying aspect is the emergence of private stool banks providing samples to the 
general public for self-administration.
Keywords: Transplantation
The guT miCRoBiome
Bacterial cells outnumber 
human cells in the healthy 
individual by at least ten-fold and 
reside in complex communities 
(microbiomes) on skin, and 
internally within the oral, respiratory, 
genital, and gastrointestinal (GI) 
tracts. The vast majority play a 
defensive role and contribute to 
maintaining health by a variety 
of means chiefly, the occupation 
of anatomical niches to deter 
overgrowth of pathogenic species, 
and involvement in immunity, 
metabolism, and synthesis of 
essential nutrients1.
The link between health and 
diet has long been recognized but 
it is in the last 50 years that our 
understanding of the complexity of 
the human intestinal microbiome 
and its relationship with health 
and disease has become clearer. 
Apart from natural physiological 
roles including immune 
system maturation and energy 
metabolism, evidence continues 
to accumulate directly implicating 
changes in gut microbiota with 
several pathological conditions 
such as colorectal cancer, 
inflammatory bowel disease, and 
obesity2. Indeed, in colon cancer, 
apart from their role as possible 
infectious agents, there is evidence 
that microbial metabolites of 
diet can also act as epigenetic 
activators of gene expression 
that may influence cancer risk 
in humans3. Moreover, perhaps 
counterintuitively, there is an 
increasing number of reports linking 
the gut microbiome with several 
other conditions (table 1) ranging 
from depression and anxiety4, to 
increased risk of cardiovascular 
disease as a consequence of 
phosphatidylcholine metabolism 
by gut bacteria5. 
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Table 1: Conditions linked to imbalance of fecal 
microbiota 
C. difficile diarrhoea and pseudomembranous colitis
Irritable bowel
Ulcerative colitis
Crohn’s
Coeliac
Colorectal cancer
Cardiovascular
Neurological (Parkinson’s, multiple sclerosis)
Diabetes
Obesity 
Relatively few bacterial species are able to live 
in the acid environment of the stomach but numbers 
increase by several orders of magnitude further 
along the GI tract with the result that bacterial cells 
constitute approximately 60% of normal fecal mass 
(figure 1). This is a complex community of archaeal 
and primarily bacterial phyla (evolutionary related 
taxonomic groups), representative of an estimated 
1,150 unique bacterial species, and each individual 
may harbor >160 of these species6, but with 
considerable variation between them. The great 
majority of the bacteria are strict anaerobes, which 
require specialized techniques for their isolation 
and identification. However, the recent advent of 
high throughput deep sequencing-based methods 
targeting the phylogenetically-informative 16S 
rRNA gene has revolutionized our understanding 
of the diversity, complexity and dynamics of the gut 
microbiota and provided fundamental insights into 
their role in health and disease7. 
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Figure 1. Distribution of bacteria in the normal human gut.
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Four phyla predominate in the GI tract. 
Firmicutes (genera including Ruminococcus, 
Clostridium, Lactobacillus) and Bacteroidetes 
(Bacteroides, Prevotella, Xylanibacter) account 
for about 90% of the flora, with Actinobacteria 
(Bifidobacterium), and Proteobacteria (coliforms) in 
the minority – although the latter group constitute 
the majority of organisms readily grown from fecal 
specimens in diagnostic microbiology laboratories. 
The myriad of species exhibit a broad range of 
substrate utilization of carbohydrates, amino acids, 
and short chain fatty acids, and are essential 
for vitamin metabolism as well as harvesting of 
energy from diet8. At this taxonomic level, the gut 
microbiome exhibits extensive conservation but 
differs more markedly at genus and species level in 
individuals which may not only be linked with diet but 
also with age and underlying health. Disturbance of 
the microbiota as a result of antimicrobial therapy or 
other factors may lead to dysbiosis (imbalance) of 
the microbiota and an associated risk of intestinal 
infection with Clostridium difficile9, and other 
inflammatory diseases.
C. difficile infection
C. difficile is a Gram-positive, anaerobic, spore-
forming bacillus which is a normal resident of 
the large intestine in about 3% of individuals. C. 
difficile infection (CDI) is manifest as a profuse 
and sometimes life-threatening diarrhea typically 
in elderly patients on broad-spectrum antibiotic 
therapy10, but also on occasion in young healthy 
individuals without prior exposure to antibiotics. 
Spores of the organism contaminate the near 
environment of patients and are able to persist 
for long periods and thereby spread infection 
in nosocomial outbreaks. There is evidence of 
widely prevalent hypervirulent clonal types (NAP 1/
ribotype O27 and NAP7/ribotype O78) in hospitals 
in several countries11 which is associated with 
increased mortality but community- acquired CDI 
caused by diverse strain genotypes appears to 
have arisen owing to increased exposure of the 
public to antibiotics.  
Surveillance reports indicate that CDI was 
responsible for about 1600 and 14,000 deaths 
in the UK and USA respectively in 2012 (Health 
Protection Agency, UK; Centers for Disease 
Control and Prevention, USA). In the UK, mortality 
rates currently appear to be decreasing from 
their previous 5 years peak, which may be due to 
better infection control practice and more effective 
prescribing of antibiotics. CDI appears to be less 
frequent in Latin America12 though this might be 
either a consequence of a lack of diagnostic testing 
or the absence of epidemic clonal types in hospitals 
and community, or both. 
Conventional treatment for severe CDI 
is a combination of oral vancomycin and 
metronidazole13, and bowel lavage, but relapse 
occurs in about 1 in 4 cases, with repeated 
relapses in some individuals. Other less studied 
approaches to treatment include novel antibiotics, 
probiotics, intravenous immunoglobulin, and more 
recently, fecal transplantation. Fidaxomicin is a 
novel narrow-spectrum macrocyclic antibiotic, 
which is approved in the USA and Europe for the 
treatment of CDI. It lacks activity against other 
major anaerobes in the gut such as Bacteroides 
spp. and Prevotella spp. and is less disruptive 
of the microbiota than vancomycin14, but clinical 
outcomes with fidaxomicin are not better than 
those with vancomycin treatment.  
Fecal microbiota transplantation
CDI
Disruption of the cycle of overgrowth of C. 
difficile in the gut of patients with symptomatic 
infections has been attempted by the oral 
administration of probiotics with a single bacterial 
species, but with little success15. An alternative 
approach to restore the balance and diversity of 
the gut microbiota and so attempt to reverse the 
dysbiosis is to introduce fecal material taken from 
a healthy person directly into the gut of the patient. 
The concept of administering fecal preparations 
as therapy dates back to the 4th century in China 
where it was used as a treatment for diarrhea in 
humans16. It was subsequently used in the 17th 
century for the treatment of ruminants and more 
lately for Salmonella infection in commercially 
reared poultry17. However, it was not until 1958 
that a fecal enema was used successfully to treat 
four patients with pseudomembranous colitis, 
predating the recognition of C. difficile as the cause 
of this disease18. Since then, several sporadic case 
reports of fecal microbiota therapy (FMT) began to 
appear in the literature but it was the cardinal study 
of van Nood et al. in 201319 which provided strong 
evidence of its efficacy for the treatment of CDI. 
This study randomized 43 patients with recurrent 
CDI, the test group received antibiotics along with 
a filtered fecal extract from a volunteer donor via 
a nasogastric tube and the control group received 
antibiotics alone. FMT was found to be more 
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than twice as effective in resolving symptoms as 
antibiotics alone and this finding resulted in early 
cessation of the trial. However, the statistical validity 
of their conclusions has been questioned by others 
chiefly on the grounds of unintended ascertainment 
bias through inequalities among the treatment 
groups20, and the relatively small sample size 
which may obscure the effects of serious adverse 
events in a minority of the patients21. Several other 
non- randomized studies have reported similarly high 
(~ 90%) success rates for CDI treatment22.
Other conditions 
It is well established that many patients with 
Crohn’s disease and ulcerative colitis have 
significant imbalances in their gut microbiota 
composition – particularly a deficiency of the phyla 
Bacteroidetes and Firmicutes23. Several case 
reports in the literature affirm that FMT is of potential 
benefit for the treatment of ulcerative colitis (UC) 
where standard treatments have failed24; see also, 
http://clinicaltrials.gov for registered clinical FMT 
trials for UC in progress (June 2014) in the USA. A 
review of 21 UC cases over 25 years treated with 
FMT by Borody25, a pioneer in the field, reported 
that 57% exhibited normal histologically uninflamed 
mucosa followed up by repeat colonoscopy for 
a mean of 33 months. However, in Borody’s 
experience, Crohn’s patients generally showed 
little or no sustained response to FMT. 
To date, there is a lack of supportive evidence 
beyond case anecdotes for the benefit of FMT 
in inflammatory bowel syndrome, metabolic 
syndrome, diabetes, and obesity. However, with 
regard to obesity, it has recently been demonstrated 
that gut bacteria from lean or obese humans induce 
similar phenotypes when introduced into the gut of 
mice; bacteria from lean donors reduced formation 
of adipose fat in the obese recipient if the mice were 
given an appropriate diet26. These findings taken 
together with the apparent correlation of increased 
blood insulin sensitivity and colonic fermentation 
products, mainly short chain fatty acids, and gut 
bacterial composition of some obese individuals27,28 
will no doubt serve to stimulate wider interest in the 
potential of FMT as a treatment for this condition.      
Safety and other issues
Given the increasing interest in the use of FMT 
to correct perceived imbalances in gut microbiota 
several key safety and practical issues need to be 
addressed by the scientific and medical community 29. 
Chief among these are i) transmission of recognized, 
and more importantly, hitherto unrecognized 
infectious agents, ii) association of certain species 
with syndromes linked to gut microbiota, iii) nature 
of fecal sample, anaerobic storage and bacterial 
viability iv) mode of administration to recipient, v) 
monitoring of efficacy, and vi) effective regulation 
and control of use.  
Donors - The composition of the gut microbiota 
of an individual is strongly linked to diet, hygiene, 
underlying health, and possibly genetic factors, but 
a common microbial core comprising three basic 
enterotypes characterized by the proportions of the 
genera Bacteroides, Prevotella or Ruminococcus 
has been proposed30. As some syndromes appear 
to be associated with specific imbalances in 
composition, it follows therefore that not all donor 
samples would be equally as effective as therapy. 
Some FMT trials have attempted to decrease 
the risk of a recipient acquiring an infection by 
using material from immediate family members. 
However, there is little evidence to suggest that 
genetic relatedness or age matching of donors to 
recipients significantly improves efficacy31.  
From a safety standpoint, screening of FMT 
donors has generally followed the framework widely 
used for blood and tissue donors covering medical 
history, high risk behaviors, recent travel, carriage of 
enteric pathogens, parasites, blood borne viruses, 
and syphilis serology (quadro 2). Some centers 
in addition screen donors for methicillin-resistant 
Staphylococcus aureus and vancomycin resistant 
enterococci; the association of the apparently 
commensal gut species Fusobacterium nucleatum 
and Streptococcus infantarius with colorectal 
cancer should also be noted32,33. Although two 
cases of norovirus gastroenteritis have been 
documented 2 and 12 days post FMT for CDI, there 
was no evidence of direct transfer of the agent 
from donors to recipient34. Nevertheless, screening 
of fecal samples by routine diagnostic methods is 
limited by the fact that these detect only currently 
known bacterial pathogens and the viral content 
remains unknown. FMT therefore has the potential 
to introduce occult infection in the recipient and 
thus compromise their future suitability as blood or 
organ donors. Non- bacterial bioactive compounds 
in stool could also be damaging to the recipient. 
These risks, particularly the lack of data on possible 
long-term adverse effects, of the treatment should 
be fully explained to prospective subjects. 
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Quadro 2: Minimum FMT Donor screen
 
Medical history (GI)
Excluded hospitalisation or antibiotic treatment (3 months); 
previous transfusion, transplant
Serology: Hepatitis A,B,C (?E), HIV, HTLV, CMV, EBV; syphilis, 
H. pylori
Culture: Salmonella, Shigella, Campylobacter, Aeromonas, 
Vibrio, E. coli O157, C. difficile 
C. difficile toxins 
Microscopy for ova cysts and parasites
Sample - Several ways of preparing the stool 
sample have been suggested but generally involve 
the use of freshly voided stool blended with 
saline from which particulate material has been 
removed by graded filtration. Some users advocate 
centrifugation of the bacteria and resuspension in 
glycerol/saline, which can be frozen at -80oC for up 
to 6 weeks in order to limit loss of viability35. This is 
diluted and up to 250 ml is delivered by nasojejunal 
tube or via a colonoscope. Prior to treatment, gut 
decontamination (vancomycin, metronidazole, 
rifampicin) and bowel lavage is recommended 
as well as the use of loperamide to maximize 
contact time of the infusate in the colon. It is 
noteworthy that there are several reports of “do-
it-yourself” treatments using enemas at home for 
inflammatory bowel diseases and ulcerative colitis 
(see, YouTube and http://www.bbc.co.uk/news/
magazine-27503660) and most disconcertingly, 
even with the use of animal stool! 
Stool substitutes - Despite the apparently 
increasing acceptability by patients of fecal therapy, 
the use of synthetic stool substitutes containing 
mixtures of gut bacteria appears to be gaining 
ground over fresh stool. A recent study reported the 
successful treatment of two patients with recurrent 
CDI, who received a laboratory prepared cocktail 
of 33 different intestinal bacterial species isolated 
from a single donor36. This approach theoretically 
facilitates tailoring the bacterial cocktail to 
imbalances of the gut microbiota in conditions 
other than CDI, with the exclusion of different 
members of the microbiota, which have been 
linked with specific syndromes. Also, safety could 
be enhanced by excluding potential pathogens 
and through screens for carriage of antibiotic, toxin 
and virulence genes. Such synthetic preparations 
would also be free of human cells and cell products 
thus reducing the risk of immune reactions. These 
preparations can be delivered as lyophilized 
material in time-release capsules or suppositories 
and this may help to reduce the natural antipathy 
of some individuals towards this form of therapy. A 
commercial synthetic stool preparation of defined 
microbial composition manufactured by Rebiotix 
was approved by the FDA for a phase II trial in 
July 2013, and other stool derived pills are in 
development in the US (Symbiotic Health, New 
York, and Seres Health, Massachusetts).
However, Borody et al.37 make a compelling 
case for the advantages of whole stool over 
selectively cultured bacteria. They point out that 
the majority of gut microbes cannot be grown in 
vitro and that culturing of isolated strains leads 
to loss of adherence ability, and hence clinical 
efficacy in comparative studies. This view is 
supported by studies of the structure and assembly 
of the complex microbial community, which found 
that bacterial gene function correlates more with 
the community as a whole than with the profile 
of individual species38. This suggests that the 
whole microbial community may contain additional 
bioactive molecules relevant to the curative 
process.
Efficacy -. The primary outcome measure of 
FMT for CDI is the resolution of symptoms and 
secondarily, prevention of relapse. A systematic 
review of 27 reports (including single cases) 
involving 317 CDI patients concluded that FMT 
resolved symptoms in 92% of subjects39. A more 
recent meta analysis which considered only those 
studies involving more than 10 patients (total 273), 
also found a high (89%) resolution rate; better 
outcomes were evident with lower gastrointestinal 
administration, but samples from related donors 
were not associated with increased efficacy40. 
Some studies have shown that following FMT 
the species profile of the recipient’s stool closely 
resembles that of the donor and this may persist 
for about a month. Indeed, with the stool substitute 
used by Petrof et al.36, DNA sequences identical 
to those in the synthetic sample constituted over 
25% of the sequences identified in the recipient’s 
gut up to 6 months after treatment indicating that 
the donor microbiota stably colonize the colon. 
However, owing to the limitations of conventional 
culture, the complexity of the gut microbiota  can 
only be demonstrated with confidence by the use of 
sophisticated metagenomic and metatranscriptomic 
techniques which allow determination of the 
relative abundance of different bacterial species 
Fecal Transplantation
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and their functional capabilities, and their relation 
to clinical outcome. In addition, there is a lack of 
information on gene expression, proteomic and 
metabolic behavior within and between members 
of the microbiota, and their impact on outcome. The 
National Institute for Health and Care Excellence of 
the UK concluded in 2014 that on current evidence 
FMT is safe and effective for the treatment of 
recurrent CDI [www.nice.org.uk/nicemedia/
live/14154/67040/67040.pdf].  
Regulation - Regulation of fecal transplants 
has been problematic owing to the difficulty of 
classification of the material used for the procedure. 
Debate has centered on whether human stool 
should be considered a tissue or a drug41. Initially 
the US Food and Drug Administration opted to 
classify it as a drug on the basis that it most fitted 
their definition of “articles intended for use in the 
diagnosis, cure, mitigation, treatment, or prevention 
of disease”, and physicians were required to file an 
investigational new drug application to use donor 
stool for the treatment of CDI. Following extensive 
pressure from patient and doctor’s groups, this 
requirement was relaxed in July 2013 but to date, 
the issue remains unresolved. However, owing to 
the unforeseen increase in demand from patients 
and physicians for FMT, revised draft guidelines 
published in March 2014 by the FDA now require 
that the donor be known either to the patient or the 
physician/provider treating the patient with CDI, 
and that the donor and stool are screened under 
the direction of the physician. No guidance has 
been given for treatment conditions other than CDI. 
This ruling will clearly have a significant impact 
on the sourcing of stools for transplant in the 
US, and effectively curtail the activities of recent 
start up companies banking stools. One of these, 
‘Openbiome’, a non profit company (http://www.
openbiome.org/) provides material at about 250 
dollars per screened stool; donors are screened 
for a wide range of infectious agents, metabolic 
syndromes, autoimmune disorders and digestive 
problems. 
Several arguments have been made against 
the ruling to ban stool banks by Internet groups 
(www.thepowerofpoop.com/fda-ban-stool-banks/) 
on the basis that it severely restricts availability of 
material as many donors prove to be unsuitable on 
screening and the high cost of testing (500-1000 
dollars). Stool banks also have the advantage of the 
necessary infrastructure for extensive screening 
of a pool of anonymized regular donors, and the 
capacity to freeze and transport material safely and 
speedily.  
Drugs are also generally characterized by 
defined consistent formulations in contrast to the 
variable microbial, metabolic and cellular complexity 
of stools. Clearly the usual drug parameters 
(pharmacokinetics, bioavailability, toxicity, etc.) are 
not applicable to fecal preparations.  An alternative 
option would be to classify human stool in its 
own category in much the same way as used for 
blood, cartilage, bone, and skin etc. The European 
Medicines Agency has yet to rule on classification 
of FMT with the natural stool product but readers 
are referred to the discussion of regulatory aspects 
of FMT for CDI from a Health Canada perspective 
which calls for rigorous donor screening and better 
standardization of fecal material and its delivery to 
the patient31. 
In conclusion, although a growing number of 
reports support the clinical efficacy of FMT for the 
treatment of CDI and possibly ulcerative colitis, 
there are several currently unresolved issues and 
concerns that need to be addressed if its use is 
to become more widespread. Key amongst these 
are, the establishment of effective standards for 
donor screens, optimal preparation of natural 
stool, influence of nonbacterial factors on efficacy, 
the most beneficial bacterial species profile for 
different dysbiotic conditions, and the wider use of 
metagenomic analysis to document and monitor 
changes in gut microbiota of the recipient. For 
natural stool, rigorous donor screening is essential 
to enhance safety but given the complexity of the 
material there will always be a low risk of occult 
infection and unintended long-term consequences 
for the recipient. Some risks may be circumvented 
by the use of synthetic stool preparations but there 
is an increasing awareness and interest among 
the general public and some may be encouraged 
by uninformed Internet sources to view this as a 
panacea treatment for the widely prevalent life 
style associated conditions (irritable bowel, type 2 
diabetes, obesity, etc.). This concern is compounded 
by the entry of the commercial market and the lack 
of clear regulation by appropriate state bodies. One 
can readily envisage the clinical consequences of 
sepsis in an individual arising from injudicious, 
uncontrolled and self-administered use of such 
materials and the ensuing media interest.
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